HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

COO

The Cooper Companies, Inc. (S&P 500)

Healthcare — Medical Instruments & Supplies

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

Buy 2.5 / 5 14 analysts
$57.41
+$0.88 (+1.56%)
Target: $66.21 (15.3%)

Price History

52-Week Range
Sign in to add COO to a watchlist or set price alerts.

Fundamentals

Market Cap$10.92B
P/E Ratio (TTM)19.73
Forward P/E12.23
EPS (TTM)$2.91
Dividend Yield-
Profit Margin13.46%
Revenue Growth0.60%
ROE6.84%
Debt/Equity33.63
Recommendation Buy 2.5
Analyst Target$66.21
Analysts14
Next Earnings Sep 9, 2026 AMC
Indexes S&P 500

Technical Indicators

RSI (14)65.9
Beta0.82
SMA 20$57.70
SMA 40$65.92
52-Week High$89.83
52-Week Low$51.01
50-Day Avg$67.49
200-Day Avg$71.62
Avg Volume$3.03M
Volume$4.54M

Performance Analysis

BULLISH

COO shows predominantly bullish signals based on its fundamentals and technicals.

~ Trading at 16% of its 52-week range.
+ RSI at 65.9 shows positive momentum.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
~ Modest revenue growth of 0.6% year-over-year.
+ Wall Street consensus is "Buy" from 14 analysts.
+ Average analyst target of $66.21 implies 15.3% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Oct 01, 2026 21:00 UTC

Back to Screener Export Report